What side effects are associated with this type of intervention?

Common treatments for Glioblastoma include radiotherapy and chemotherapy agents like temozolomide. Radiotherapy can cause side effects such as fatigue, hair loss, skin changes, and inflammation of the brain (radiation necrosis). Chemotherapy with temozolomide often leads to nausea, vomiting, loss of appetite, and myelosuppression (reduced blood cell production). Inhibitors of DNA repair mechanisms, like the ATM kinase inhibitor AZD1390, can enhance the effects of radiotherapy but may also increase the risk of side effects such as increased sensitivity to radiation, leading to more pronounced fatigue, skin reactions, and potential for more severe brain inflammation.

What prior FDA approvals exist?

The FDA has approved several treatments for Glioblastoma, including temozolomide, which is often used in combination with radiotherapy. Temozolomide works by damaging the DNA of cancer cells, thereby enhancing the effects of radiotherapy. Another relevant treatment is bevacizumab, an anti-angiogenic drug that inhibits the growth of blood vessels in tumors. While specific ATM kinase inhibitors like AZD1390 are still under investigation, these approved treatments share the common goal of enhancing radiotherapy's effectiveness by targeting cancer cell survival mechanisms.

What other types of research exist?

Promising alternatives to AZD1390 for Glioblastoma patients include ATR inhibitors like AZD6738, which has shown radiosensitization effects in multiple cancer cell lines, and PARP inhibitors, which are effective in tumors with DNA repair deficiencies. Additionally, IDH-targeted therapies such as Ivosidenib and Vorasidenib are being explored for IDH-mutant gliomas and may offer new treatment avenues.

← Back to Search

ATM Kinase Inhibitor

AZD1390 for Glioblastoma

Phase < 1

Recruiting

Led By Nader Sanai, MD

Research Sponsored by Nader Sanai

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 month progression-free survival (pfs6) rate measured from the time of surgery to date of recurrence.

Awards & highlights

Study Summary

This trial will test a new drug, AZD1390, for people with a certain type of brain cancer. Researchers will see how well the drug works on its own and in combination with standard radiation therapy.

Who is the study for?

This trial is for adults over 18 with newly diagnosed or recurrent WHO Grade 4 glioma (a type of brain tumor) who are planning to have radiation. They must have measurable disease, stable seizures if present, and good organ function. Pregnant women, those with certain heart conditions or severe infections, and individuals on specific medications are excluded.Check my eligibility

What is being tested?

The study tests AZD1390 in combination with standard radiotherapy. It includes a Phase 0 part where patients' PK response is assessed and a Phase 1b expansion for responders. The goal is to see how well AZD1390 works alongside usual cancer treatments.See study design

What are the potential side effects?

Potential side effects of AZD1390 may include reactions related to the immune system, liver issues reflected by blood tests, possible impact on bone marrow leading to blood disorders, digestive disturbances like changes in pancreatic enzymes levels, and general symptoms such as fatigue.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 month progression-free survival (pfs6) rate measured from the time of surgery to date of recurrence.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 month progression-free survival (pfs6) rate measured from the time of surgery to date of recurrence.

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 month progression-free survival (pfs6) rate measured from the time of surgery to date of recurrence. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Phase 0: The relative pharmacokinetics (PK) of AZD1390 in tumor tissue from Grade 4 glioma participants treated with AZD1390

Phase 1b: Examine the rate of 6-month progression-free survival glioma participants with demonstrated PK effect.

Secondary outcome measures

Adverse events

Deaths

Drug-related toxicity

+3 more

Trial Design

3Treatment groups

Experimental Treatment

Group I: Arm C: Newly-diagnosed Grade 4 GliomaExperimental Treatment1 Intervention

Group II: Arm B: Recurrent Grade 4 Glioma Dose EscalationExperimental Treatment1 Intervention

Group III: Arm A: Recurrent Grade 4 Glioma Surgical Cohort Time EscalationExperimental Treatment1 Intervention

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for Glioblastoma include radiotherapy and chemotherapy. Radiotherapy damages the DNA of cancer cells, leading to cell death, but its effectiveness is often limited by the cancer cells' ability to repair this damage. Agents like AZD1390, an ATM kinase inhibitor, enhance the effects of radiotherapy by preventing DNA repair in cancer cells. This mechanism is significant for Glioblastoma patients as it can potentially improve the efficacy of standard treatments, leading to better clinical outcomes and prolonged survival.

Find a Location

Who is running the clinical trial?

AstraZenecaIndustry Sponsor

4,289 Previous Clinical Trials

288,620,161 Total Patients Enrolled

14 Trials studying Glioblastoma

966 Patients Enrolled for Glioblastoma

Nader SanaiLead Sponsor

8 Previous Clinical Trials

291 Total Patients Enrolled

6 Trials studying Glioblastoma

189 Patients Enrolled for Glioblastoma

Ivy Brain Tumor CenterOTHER

11 Previous Clinical Trials

790 Total Patients Enrolled

8 Trials studying Glioblastoma

666 Patients Enrolled for Glioblastoma

Media Library

AZD1390 (ATM Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05182905 — Phase < 1

Glioblastoma Research Study Groups: Arm A: Recurrent Grade 4 Glioma Surgical Cohort Time Escalation, Arm B: Recurrent Grade 4 Glioma Dose Escalation, Arm C: Newly-diagnosed Grade 4 Glioma

Glioblastoma Clinical Trial 2023: AZD1390 Highlights & Side Effects. Trial Name: NCT05182905 — Phase < 1

AZD1390 (ATM Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05182905 — Phase < 1

~0 spots leftby Jul 2024

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.